Taysha Gene Therapies is trading at $4.22, up +5.36%, with the gain appearing mainly aligned with biotech-sector strength; available information does not establish a direct cause.
- Supplied sector data shows XBI up 2.18% during regular trading.
- No new company-specific catalyst was reported for October 27, 2026, and a market-data search likewise found none.
- Recent attention around the Rett syndrome program followed an October 26 article; that coverage was not a new announcement today.